Eric DAUGAS
Nephrology department, Bichat Hospital, APHP, Paris · Assistance Publique - Hôpitaux de Paris
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric DAUGAS as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:23 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04702256 · Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMFAssistance Publique - Hôpitaux de Paris · recruiting · Lupus Nephritis, Systemic Lupus Erythematosus (SLE) · study director
- N/ANCT03921398 · Identifying New Therapeutic Targets for Lupus TreatmentAssistance Publique - Hôpitaux de Paris · completed · Lupus Nephritis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:23 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.N Engl J Med · 2014780 citationsRCR 27.9
- Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.Ann Rheum Dis · 2018150 citationsRCR 7.1
- Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.Ann Rheum Dis · 202273 citationsRCR 7.4
- Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.Nephrol Dial Transplant · 201459 citationsRCR 2.2
- Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial.J Am Coll Cardiol · 202155 citationsRCR 3.7
- Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study.J Am Soc Nephrol · 202249 citationsRCR 4.5
- Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life.Clin Exp Rheumatol · 201629 citationsRCR 1.4
- 21 citationsRCR 1.1
- Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse.RMD Open · 202412 citationsRCR 1.9
- Efficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial.Nephrol Dial Transplant · 20237 citationsRCR 0.9